Explore CJC-1295 DAC dosage trends, reconstitution volumes, and vial size patterns from WPA peptide calculator sessions.
CJC-1295 DAC is a long-acting GHRH analog modified with a drug affinity complex (DAC) that extends its half-life to several days, allowing for less frequent injections than the non-DAC form. This data shows the dose amounts, vial sizes, and bacteriostatic water volumes researchers most commonly select when reconstituting CJC-1295 DAC.
Standalone CJC-1295 DAC is the GHRH side of a stack run on its own, and the molecule that makes it possible is the drug-affinity-complex (DAC) linker ConjuChem engineered onto the parent Modified GRF 1-29 backbone in the early 2000s. , Journal of Clinical Endocrinology & Metabolism 2006 — "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults" — which showed that a single subcutaneous dose of CJC-1295 DAC produced a sustained elevation in IGF-1 of up to 28 days, with mean GH levels rising to roughly 8-fold over baseline at steady state and a half-life on the order of 5-8 days.
CJC-1295 with DAC is the long-acting GHRH-analog research peptide most often sourced for GH-axis protocols where a single weekly dose is preferred. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.
Like the no-DAC variant, CJC-1295 DAC binds the GHRH receptor on pituitary somatotropes; the albumin tether converts what would be a brief, pulsatile signal into a continuous receptor exposure. Continuous activation raises baseline IGF-1 substantially but partially flattens the body's natural GH-pulse architecture — a pharmacologic difference that distinguishes it from the no-DAC variant clinicians use to preserve endogenous pulsatility.
A Phase 1 single-ascending-dose study in healthy adults (Teichman et al., JCEM 2006) documented sustained ~1.5–3× elevation of IGF-1 lasting 6+ days after a single subcutaneous injection. ConjuChem advanced CJC-1295 into Phase 2 trials for GH-deficient adults and pediatric short stature in 2007–2008; the program was halted following the death of a participant during a Phase 2 lipodystrophy trial. No Phase 3 program followed and CJC-1295 has no active sponsor today.
CJC-1295 DAC has a reported half-life of ~6–8 days, and the dose intervals researchers model most often fall around once or twice weekly. The DAC version binds to blood proteins and lasts about a week, so it builds to a steady level over several weeks and provides a constant GH-releasing signal. It is catalogued under Muscle Peptides on WPA.
320 CJC-1295 DAC reconstitution calculations have been logged by the WPA community. The most common dose entered is 1mg (87 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 5mg (206 sessions). The most common dosing frequency is once weekly (41 logged protocols), followed by 2x/week (9).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.